BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 1897909)

  • 1. Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: a positron emission tomographic study.
    Brooks DJ; Ibanez V; Playford ED; Sawle GV; Leigh PN; Kocen RS; Harding AE; Marsden CD
    Ann Neurol; 1991 Aug; 30(2):166-71. PubMed ID: 1897909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
    Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
    Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
    Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
    Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
    Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
    Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease.
    Broussolle E; Dentresangle C; Landais P; Garcia-Larrea L; Pollak P; Croisile B; Hibert O; Bonnefoi F; Galy G; Froment JC; Comar D
    J Neurol Sci; 1999 Jul; 166(2):141-51. PubMed ID: 10475108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia.
    Turjanski N; Bhatia K; Burn DJ; Sawle GV; Marsden CD; Brooks DJ
    Neurology; 1993 Aug; 43(8):1563-8. PubMed ID: 8351012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D2 receptor binding in dopa-responsive dystonia.
    Künig G; Leenders KL; Antonini A; Vontobel P; Weindl A; Meinck HM
    Ann Neurol; 1998 Nov; 44(5):758-62. PubMed ID: 9818931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal dopaminergic system in dopa-responsive dystonia: a multi-tracer PET study shows increased D2 receptors.
    Rinne JO; Iivanainen M; Metsähonkala L; Vainionpää L; Pääkkönen L; Någren K; Helenius H
    J Neural Transm (Vienna); 2004 Jan; 111(1):59-67. PubMed ID: 14714216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD.
    Kemppainen N; Ruottinen H; Nâgren K; Rinne JO
    Neurology; 2000 Jul; 55(2):205-9. PubMed ID: 10908891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.
    Turjanski N; Lees AJ; Brooks DJ
    Neurology; 1999 Mar; 52(5):932-7. PubMed ID: 10102408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
    Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
    J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-[18F]fluoro-L-dopa uptake and [76Br]bromolisuride binding in the excitotoxically lesioned caudate-putamen of nonhuman primates studied using positron emission tomography.
    Hantraye P; Loc'H C; Maziere B; Khalili-Varasteh M; Crouzel C; Fournier D; Yorke JC; Stulzaft O; Riche D; Isacson O
    Exp Neurol; 1992 Feb; 115(2):218-27. PubMed ID: 1531196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.
    Frost JJ; Rosier AJ; Reich SG; Smith JS; Ehlers MD; Snyder SH; Ravert HT; Dannals RF
    Ann Neurol; 1993 Sep; 34(3):423-31. PubMed ID: 8363363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mu-receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man.
    Hagelberg N; Kajander JK; Någren K; Hinkka S; Hietala J; Scheinin H
    Synapse; 2002 Jul; 45(1):25-30. PubMed ID: 12112410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data.
    Burn DJ; Sawle GV; Brooks DJ
    J Neurol Neurosurg Psychiatry; 1994 Mar; 57(3):278-84. PubMed ID: 8158173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.